AbbVie in charts: Revenues from Humira -58%, Skyrizi +62%, Rinvoq +42% Y/Y (ABBV:NYSE)

AbbVie (ABBV) reported stronger-than-expected Q2 earnings, with non-GAAP EPS of $2.97 and revenue of $15.42 billion, both surpassing analyst estimates. This outperformance was primarily driven by robust growth in key immunology drugs Skyrizi (+62% Y/Y) and Rinvoq (+42% Y/Y), successfully offsetting a significant 58% year-over-year decline in Humira revenue. The company's reported $1 billion acquisition talks for Gilgamesh further underscore its strategic focus on portfolio diversification and future growth.

Analysis

AbbVie (ABBV) delivered second-quarter results that surpassed analyst expectations, with non-GAAP EPS of $2.97 beating by $0.06 and revenue of $15.42 billion exceeding forecasts by $390 million. The central dynamic of the quarter was the successful management of its portfolio transition; the steep 58% year-over-year revenue decline from its legacy blockbuster, Humira, was effectively offset by the robust performance of its key growth assets. Specifically, Skyrizi and Rinvoq demonstrated significant commercial momentum, with sales surging 62% and 42% year-over-year, respectively. This strong operational execution is complemented by a forward-looking growth strategy, underscored by reports that AbbVie is in talks for a potential $1 billion acquisition of Gilgamesh, signaling a clear intent to further diversify its pipeline and secure future revenue streams.

Key Decisions for Investors

• Investors should assess AbbVie's performance based on the growth trajectory of Skyrizi and Rinvoq, as their combined strength is proving sufficient to navigate the well-documented Humira revenue erosion.
• The reported $1 billion acquisition talks for Gilgamesh should be monitored as a key strategic development, as a successful deal would reinforce the company's commitment to pipeline expansion and long-term growth.
• Given the earnings beat and clear evidence of a successful strategic transition, the current results could justify maintaining or increasing exposure for investors confident in the continued execution of the post-Humira growth plan.